Merck has made the decision to end 2 clinical trials evaluating its programmed death receptor-1 (PD-1)-blocking antibody, Keytruda ® (pembrolizumab). The Company is discontinuing the phase 3 ...
The trial is evaluating the investigational fixed-dose combination (coformulation) of vibostolimab, an anti-TIGIT antibody, and pembrolizumab (Keytruda), Merck’s anti-PD-1 therapy, in combination ...
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J., September 15, ...